Mask Group 8@2x

Unlocking Immunology

headline
Union 10
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology.

Our Lead Candidate

Introduction to Tharimmune and TH104 by Randy Milby, Chief Executive Officer

Play Video about home vid

About Us

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company’s lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritus or “uncontrollable itching” in PBC, a rare and orphan liver disease with no known cure.

Mask Group 26
Group 1559@2x

LATEST FROM THARIMMUNE